1. Home
  2. MOB vs ATOS Comparison

MOB vs ATOS Comparison

Compare MOB & ATOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Mobilicom Limited

MOB

Mobilicom Limited

N/A

Current Price

$1.43

Market Cap

30.9M

Sector

Real Estate

ML Signal

N/A

Logo Atossa Therapeutics Inc.

ATOS

Atossa Therapeutics Inc.

N/A

Current Price

$1.80

Market Cap

25.9M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
MOB
ATOS
Founded
2008
2009
Country
Israel
United States
Employees
N/A
N/A
Industry
Real Estate Investment Trusts
Biotechnology: Pharmaceutical Preparations
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
30.9M
25.9M
IPO Year
2021
2010

Fundamental Metrics

Financial Performance
Metric
MOB
ATOS
Price
$1.43
$1.80
Analyst Decision
Strong Buy
Buy
Analyst Count
2
2
Target Price
$11.00
★ $19.00
AVG Volume (30 Days)
★ 174.1K
48.0K
Earning Date
08-13-2026
11-10-2026
Dividend Yield
N/A
N/A
EPS Growth
★ N/A
N/A
EPS
★ N/A
N/A
Revenue
N/A
★ $1,758.00
Revenue This Year
$76.34
N/A
Revenue Next Year
$109.65
N/A
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.38
$0.53
52 Week High
$9.78
$7.56

Technical Indicators

Market Signals
Indicator
MOB
ATOS
Relative Strength Index (RSI) 22.71 31.30
Support Level N/A N/A
Resistance Level $6.89 $2.60
Average True Range (ATR) 0.32 0.17
MACD -0.07 -0.04
Stochastic Oscillator 5.56 1.54

Price Performance

Historical Comparison
MOB
ATOS

About MOB Mobilicom Limited

Mobilicom Ltd is a provider of cybersecurity and smart solutions for drones, robotics & autonomous platforms. As a high-tech company, it designs, develops, and delivers smart solutions targeting global drone, robotics, and autonomous system manufacturers. Its products include OS3 Platform Software, ICE Cybersecurity Software, MCU Mesh Networking, SkyHopper Datalinks, Mobile Ground Control Stations and System Engineering Services.

About ATOS Atossa Therapeutics Inc.

Atossa Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the development of proprietary medicines for oncology, with a focus on breast cancer and related conditions. The company's lead product candidate, oral (Z)-endoxifen, is a selective estrogen receptor modulator and degrader (SERM/SERD) in Phase 2 clinical development, being evaluated for the treatment and prevention of breast cancer and other indications.

Share on Social Networks: